Advertisement
Advertisement
U.S. markets open in 1 hour 56 minutes
Advertisement
Advertisement
Advertisement
Advertisement

ATI Physical Therapy, Inc. (ATIP)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
1.0000-0.0400 (-3.85%)
At close: 04:00PM EDT
0.9500 -0.05 (-5.00%)
After hours: 07:39PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close1.0400
Open1.0200
Bid0.0000 x 1400
Ask0.0000 x 1400
Day's Range1.0000 - 1.0450
52 Week Range0.8550 - 4.5700
Volume339,045
Avg. Volume780,711
Market Cap207.149M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-4.8920
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.68
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ATIP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ATI Physical Therapy, Inc.
    Analyst Report: 23andMe Holding Co.23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates.
    Rating
    Fair Value
    Economic Moat
    4 months agoMorningstar
View more
  • PR Newswire

    ATI Physical Therapy Tops CMS List of Best Patient Quality for Second Consecutive Year

    ATI Physical Therapy ("ATI" or the "Company") today announced that it has again earned the highest level of distinction by the Merit-Based Incentive Payment System (MIPS) for quality patient care in 2021. For the second consecutive year, ATI received the highest possible score, ranking in the 100th percentile of providers delivering outstanding patient outcomes, according to the Center for Medicare and Medicaid Services' (CMS) Quality Payment Program (QPP). The Company was ranked an "exceptional

  • PR Newswire

    ATI Physical Therapy Announces Healthcare Veteran Eimile Tansey as Chief People Officer

    ATI Physical Therapy ("ATI" or the "Company") (NYSE: ATIP), the largest single-branded outpatient physical therapy provider in the United States, today announced that Eimile Tansey will be joining the company later this month as Chief People Officer. Tansey will lead ATI's priority initiatives to drive excellence in employee recruiting, hiring, training and retention as critical elements of the Company's growth strategy.

  • PR Newswire

    ATI Physical Therapy Reports Second Quarter 2022 Results; Revises Guidance for Full Year 2022

    ATI Physical Therapy, Inc. ("ATI" or the "Company") (NYSE: ATIP), the largest single-branded outpatient physical therapy provider in the United States, today reported financial results for the second quarter ended June 30, 2022.

Advertisement
Advertisement